344-53-6

Upstream product

• 445-03-4 4-chloro-2-(trifluoromethyl)aniline 
• 108-24-7 acetic anhydride 
• 118-83-2 5-chloro-2-nitrotrifluoromethylbenzene 
• 393-11-3 4-nitro-3-(trifluoromethyl)benzeneamine 
• 539-03-7 N-(4-chlorophenyl)acetamide 
• 344-62-7 N-[2-(trifluoromethyl)phenyl]acetamide 
• 2926-29-6 Langlois reagent 
• 74383-34-9 4-chlorobenzen-2-d-amine 
• 106-47-8 4-chloro-aniline 
• 75-36-5 acetyl chloride 
• 76-05-1 trifluoroacetic acid 

Downstream Products

• 1573117-59-5 1-(4-chloro-2-(trifluoromethyl)phenyl)-5-methyl-1H-tetrazole 
• 62924-50-9 4-chloro-6-(trifluoromethyl)-2-nitroaniline 
• 156425-10-4 5-chloro-3-trifluoromethyl-1,2-phenylenediamine 
• 172215-95-1 4-chloro-6-(trifluoromethyl)-2-nitroacetanilide 

Relevant academic research and scientific papers

Complementary Site-Selective Halogenation of Nitrogen-Containing (Hetero)Aromatics with Superacids

Site-selective functionalization of arenes that is complementary to classical aromatic substitution reactions remains a long-standing quest in organic synthesis. Exploiting the generation of halenium ion through oxidative process and the protonation of the nitrogen containing function in HF/SbF5, the chlorination and iodination of classically inert Csp2?H bonds of aromatic amines occurs. Furthermore, the superacid-promoted (poly)protonation of the molecules acts as a protection, favoring the late-stage selective halogenation of natural alkaloids and active pharmaceutical ingredients.

Visible-light-induced Pd-catalyzed: Ortho -trifluoromethylation of acetanilides with CF3SO2Na under ambient conditions in the absence of an external photocatalyst

A visible-light-induced Pd-catalyzed ortho-trifluoromethylation of acetanilides with CF3SO2Na was developed. The reaction proceeded smoothly at room temperature in air without any external photocatalyst or additive, providing the desired products in moderate to good yields with good functional group tolerance and regioselectivity.

Preparation 2-trifluoromethyl-4-substituted aniline compounds

The invention relates to a method for preparing 2-trifluoromethyl-4-substituted phenylamine and 2-trifluoromethyl-4-substituted acetanilide. The method for preparing the2-trifluoromethyl-4-substituted phenylamine and 2-trifluoromethyl-4-substituted acetanilide comprises the following main step: in the presence of sodium trifluoromethanesulfonate and tert-butyl hydroperoxide but no metal salt catalyst and under the stirring condition, maintaining a 4-substituted phenylamine compound (concrete structure shown in a formula II is described in the specification) in a reaction medium of mixture composed of dichloromethane and water at the temperature of 0-25 DEG C for 72-120 hours, so that the 2-trifluoromethyl-4-substituted phenylamine target product is obtained. The preparation method provided by the invention has potential commercial value.

Visible-light-promoted radical C-H trifluoromethylation of free anilines

The trifluoromethyl-substituted anilines are biologically active compounds and useful building blocks. In this communication, we have developed the first visible-light-induced radical trifluoromethylation of free anilines with the commercially available and easily handled Togni reagent at room temperature. The resulting products were successfully transformed into a variety of valuable fluorine-containing molecules and heterocyclic compounds. This protocol provides an economical and powerful route to trifluoromethylated free anilines.

Copper-free direct C-H trifluoromethylation of acetanilides with sodium trifluoromethanesulfinate

A copper-free direct C-H ortho trifluoromethylation of electron-deficient 4-substituted acetanilides using Langlois reagent (NaSO2CF3) as the CF3 source in the presence of tert-butyl hydroperoxide (tBuOOH, TBHP) was developed.

Palladium-catalyzed trifluoromethylation of aromatic C-H bond directed by an acetamino group

The first palladium-catalyzed ortho-trifluoromethylation of the aromatic C-H bond directed by an acetamino group is reported. This method provides an efficient and green approach to synthesize the highly biological potential key structure of ortho-CF3 acetanilides and anilines.

Glycine receptor antagonists and the use thereof

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal. Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.